ACM
RMD icon

Accent Capital Management’s ResMed RMD Stock Holding History

Accent Capital Management’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.59K Sell
16
-2
-11% -$498 ﹤0.01% 301
2025
Q4 		$4.34K Hold
18
– – ﹤0.01% 311
2025
Q3 		$4.93K Buy
+18
New +$4.92K ﹤0.01% 325

Other funds holding RMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Accent Capital Management's RMD Position: Q1 2026 in Review

Accent Capital Management reduced its ResMed (RMD) stake by 11% in Q1 2026, selling an estimated $498 and leaving 16 shares worth $3.59K. The position accounts for ﹤0.01% of the portfolio, ranked #301.

Accent Capital Management first reported a position in RMD in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.93K in Q3 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Accent Capital Management held 16 shares of ResMed worth $3.59K as of Q1 2026.
  • Accent Capital Management sold 2 ResMed shares in Q1 2026, an estimated $498.
  • ResMed made up ﹤0.01% of Accent Capital Management's portfolio in Q1 2026, its #301 holding.
  • Accent Capital Management first reported a position in ResMed in Q3 2025 and has held it in 3 quarters since.
  • Accent Capital Management's ResMed position peaked at $4.93K in Q3 2025.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Accent Capital Management's 13F filing for Q1 2026, filed 11 May 2026.